消栓通络胶囊联合尤瑞克林治疗急性脑梗死的临床研究

目的 观察消栓通络胶囊联合尤瑞克林治疗急性脑梗死的临床疗效。方法 选择2019年5月—2022年5月在石家庄市人民医院诊治的106例急性脑梗死患者，按照随机数字表法分对照组（53例）和治疗组（53例）。对照组静脉滴注注射用尤瑞克林，0.15PNA单位/次，溶于生理盐水100mL，1次/d。在对照组的基础上，治疗组口服消栓通络胶囊，6粒/次，3次/d。两组用药14d。观察两组患者临床疗效，比较治疗前后两组患者症状改善时间，NIHSS评分，Barthel指数，血清细胞间黏附分子-1（ICAM-1）、血管细胞间黏附分子-1（VCAM-1）、白细胞介素-8（IL-8）和血管内皮生长因子（VEGF）水平，及不良反应。结果 治疗后，治疗组总有效率（98.11%）明显高于对照组（81.13%，P＜0.05）。治疗后，治疗组症状改善时间均明显早于对照组（P＜0.05）。治疗后，两组NIHSS评分明显降低，而Barthel指数评分明显升高（P＜0.05），且治疗组评分明显好于对照组（P＜0.05）。治疗后，两组血清IL-8、ICAM-1、VCAM-1水平明显降低，而VEGF水平明显升高（P＜0.05），且治疗组血清因子水平明显好于对照组（P＜0.05）。治疗后，治疗组患者不良反应发生率明显低于对照组（P＜0.05）。结论 消栓通络胶囊联合注射用尤瑞克林治疗急性脑梗死效果确切，可有效改善患者缺血区域血供，改善脑神经功能。

Clinical study on Xiaoshuan Tongluo Capsules combined with uriculin in treatment of acute ischemic stroke

Objective To investigate the effect of Xiaoshuan Tongluo Capsules combined with uriculin in treatment of acute ischemic stroke. Methods Patients (106 cases) with acute ischemic stroke in Shijiazhuang People''s Hospital from May 2019 to May 2022 were divided into control (53 cases) and treatment (53 cases) group according to the random number table method. Patients in the control group were iv administered with Urinary Kallidinogenase for injection, 0.15 PNA/time dissolved in normal saline 100 mL, once daily. Patients in the treatment group po administered with Xiaoshuan Tongluo Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluation was evaluated, the improvement time of symptom, NIHSS score, Barthel index, the levels of serological indexes IL-8, ICAM-1, VCAM-1, and VEGF, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (98.11%) was significantly higher than that of the control group (81.13%, P<0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P<0.05). After treatment, the NIHSS score in two groups were significantly decreased, while the Barthel index score were significantly increased (P<0.05), and the scores in the treatment group were significantly better than that of the control group (P<0.05). After treatment, the serum levels of IL-8, ICAM-1, and VCAM-1 in two groups were significantly decreased, while the level of VEGF were significantly increased, and the level of serum factors in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the incidence of adverse reactions in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion The effect of Xiaoshuan Tongluo Capsules combined with uriculin in treatment of acute ischemic stroke is definite, and can effectively improve the blood supply and cerebral nerve function in the ischemic area of the patients.